Developer docs
API playgroundTry for free, no card

Search company profiles

PredictImmune

Full company profile

uuid0002m6f

Namestring
PredictImmune
Company typeenum
Private
Founded yearint
2017
Descriptiontext

PredictImmune is a Cambridge, UK-based private biotechnology company founded in 2017 that develops prognostic tools to support physicians treating patients with immune-mediated disease by predicting long-term clinical outcomes. The company's offering targets clinical decision-making in conditions such as inflammatory bowel disease — a focus reinforced by its 2023 partnership with the Crohn's & Colitis Foundation. Its core product is positioned as a prognostic test or platform, anchored in biomarker science originating from University of Cambridge research and developed via a leadership team combining scientific (CSO Eoin McKinney), clinical (CMO Kenneth Smith), and platform-delivery (VP Paul Lyons) expertise.

The company's revenue mechanics, pricing model, and go-to-market strategy are not disclosed in the available sources. Capital has been raised across six funding events cumulatively totaling approximately $31.4M (2017–2023), sourced from UK-aligned institutional and disease-foundation backers — Parkwalk Advisors, University of Cambridge Enterprise, Wren Capital, Wellcome Trust, Innovate UK, Business Growth Fund, Cambridge Innovation Capital, and the Crohn's & Colitis Foundation — implying reliance on non-dilutive and venture funding rather than commercial product revenue. Headcount sits at 11–50 employees, consistent with a translational-stage organization; no product pricing, customer logos, or commercial distribution channels were disclosed.

The firm's strategic posture is best characterized as clinical validation and platform maturation: founder-scientists run the R&D agenda, an independent chairman and CFO signal governance readiness, and disease-foundation partnerships point toward regulated diagnostic pathways (likely UKCA/CE-marked in vitro diagnostics) rather than direct-to-consumer or SaaS distribution. Absent disclosed revenue, the business model is best read as pre-commercial, with monetization to follow regulatory clearance, reimbursement, and clinical adoption milestones.

Short descriptiontext

PredictImmune is a Cambridge, UK-based private biotech developing prognostic tools that help physicians predict long-term clinical outcomes in patients with immune-mediated diseases, with a focus on inflammatory bowel disease. The company is anchored in Cambridge-linked research and funded by UK institutional and disease-foundation backers.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
immune disease prognostics, clinical prognostic biomarkers, inflammatory disease diagnostics, physician decision support, biomarker prediction platform
Industry3 codes
PRIMARYHLAAAMAE
Predictive Biomarkers for Therapy Selection (response/non-response stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLACAGAE
Risk Stratification, Early Warning Scores & Predictive Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Prognostics Software
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

PredictImmune develops and provides tools to physicians for use in the treatment of patients with immune-mediated disease, focused on predicting long-term clinical prognosis. The company applies proprietary biomarker science and predictive analytics to translate complex immunological data into clinically actionable long-term outcome forecasts that support personalized treatment planning.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1PredictImmune Prognostic Platform
CategoryClinical Prognostics / Decision Support Software
Description

Physician-facing prognostic platform that predicts long-term clinical outcomes for patients with immune-mediated disease (notably inflammatory bowel disease), supporting personalized treatment planning and risk stratification.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Prometheus (a Nestlé Health Science company) develops and markets IBD diagnostic and prognostic testing (e.g., IBD Serology 7, PROMETHEUS® Crohn's Prognostic) — directly comparable to PredictImmune as both serve gastroenterologists with biomarker-based prognosis to inform treatment decisions in Crohn's disease and ulcerative colitis.

TypeDirect peer
Description

Exagen markets proprietary blood-based diagnostic and prognostic tests for autoimmune diseases (e.g., AVISE CTD, AVISE Lupus Prognostic) and sells its assays through a CLIA lab to rheumatologists — directly analogous to PredictImmune's physician-facing prognostic-testing model in immune-mediated disease.

TypeBroad incumbent
Description

Myriad is an established molecular diagnostics company offering prognostic and predictive tests (e.g., Vectra DA for RA disease activity, risk-assessment panels) that target specialists managing autoimmune/immune-mediated disease — comparable as a broad incumbent providing physician-facing prognostic biomarker testing.

TypeEmerging player
Description

Adaptive applies immune-receptor sequencing and immune-profiling to characterize immune-mediated disease states and predict clinical outcomes, analogous to PredictImmune's biomarker-based prognosis in immune-mediated conditions — a partial-overlap emerging player with an adjacent technology platform.

TypeEmerging player
Description

CareDx is a specialty diagnostics company whose AlloSure/AlloMap franchise monetizes prognostic biomarker testing paid for by transplant centers and payers — relevant as a comparable commercial model where a single-disease prognostic biomarker test is sold into a specialist physician channel.

TypeBroad incumbent
Description

Eurofins operates a global specialty diagnostics and clinical-testing platform, including autoimmune and IBD biomarker services to clinicians; relevant as a broad incumbent that could partner with, acquire, or compete against PredictImmune's prognostic testing platform.

TypeEmerging player
Description

Vedanta develops microbiome-based therapies for immune-mediated disease (including IBD) and operates in the same clinical/scientific Cambridge-cluster ecosystem; comparable as an immune-mediated-disease platform company pursuing biomarker-driven patient stratification in overlapping indications.

TypeEmerging player
Description

Progentec develops biomarker-driven diagnostics for autoimmune diseases (e.g., lupus, RA) intended to predict flares and disease progression — a direct functional competitor in the physician-facing prognostic-test niche that PredictImmune targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PredictImmune

Clinical Prognostics Softwarepredictimmune.com

PredictImmune is a Cambridge, UK-based private biotech developing prognostic tools that help physicians predict long-term clinical outcomes in patients with immune-mediated diseases, with a focus on inflammatory bowel disease. The company is anchored in Cambridge-linked research and funded by UK institutional and disease-foundation backers.

What PredictImmune does

PredictImmune is a Cambridge, UK-based private biotechnology company founded in 2017 that develops prognostic tools to support physicians treating patients with immune-mediated disease by predicting long-term clinical outcomes. The company's offering targets clinical decision-making in conditions such as inflammatory bowel disease — a focus reinforced by its 2023 partnership with the Crohn's & Colitis Foundation. Its core product is positioned as a prognostic test or platform, anchored in biomarker science originating from University of Cambridge research and developed via a leadership team combining scientific (CSO Eoin McKinney), clinical (CMO Kenneth Smith), and platform-delivery (VP Paul Lyons) expertise.

The company's revenue mechanics, pricing model, and go-to-market strategy are not disclosed in the available sources. Capital has been raised across six funding events cumulatively totaling approximately $31.4M (2017–2023), sourced from UK-aligned institutional and disease-foundation backers — Parkwalk Advisors, University of Cambridge Enterprise, Wren Capital, Wellcome Trust, Innovate UK, Business Growth Fund, Cambridge Innovation Capital, and the Crohn's & Colitis Foundation — implying reliance on non-dilutive and venture funding rather than commercial product revenue. Headcount sits at 11–50 employees, consistent with a translational-stage organization; no product pricing, customer logos, or commercial distribution channels were disclosed.

The firm's strategic posture is best characterized as clinical validation and platform maturation: founder-scientists run the R&D agenda, an independent chairman and CFO signal governance readiness, and disease-foundation partnerships point toward regulated diagnostic pathways (likely UKCA/CE-marked in vitro diagnostics) rather than direct-to-consumer or SaaS distribution. Absent disclosed revenue, the business model is best read as pre-commercial, with monetization to follow regulatory clearance, reimbursement, and clinical adoption milestones.

PredictImmune firmographics

Firmographics
Name
PredictImmune
Website
https://predictimmune.com
Company type
Private
Founded year
2017
Headcount range
11–50 employees
Short description
PredictImmune is a Cambridge, UK-based private biotech developing prognostic tools that help physicians predict long-term clinical outcomes in patients with immune-mediated diseases, with a focus on inflammatory bowel disease. The company is anchored in Cambridge-linked research and funded by UK institutional and disease-foundation backers.
Ownership category
akta.pro rank

PredictImmune industry classification

Industry
Product category
Clinical Prognostics Software
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAE
Predictive Biomarkers for Therapy Selection (response/non-response stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLACAGAE
Risk Stratification, Early Warning Scores & Predictive Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Immune disease prognostics
  • Clinical prognostic biomarkers
  • Inflammatory disease diagnostics
  • Physician decision support
  • Biomarker prediction platform

Where PredictImmune is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Markets served

PredictImmune business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations

PredictImmune product offering

Product offering

Core offering

PredictImmune develops and provides tools to physicians for use in the treatment of patients with immune-mediated disease, focused on predicting long-term clinical prognosis. The company applies proprietary biomarker science and predictive analytics to translate complex immunological data into clinically actionable long-term outcome forecasts that support personalized treatment planning.

Differentiator

Problem solved

Functional benefit

Products and services

  • PredictImmune Prognostic Platform Physician-facing prognostic platform that predicts long-term clinical outcomes for patients with immune-mediated disease (notably inflammatory bowel disease), supporting personalized treatment planning and risk stratification.

Companies that use PredictImmune

Customer profile

Ideal customer profiles1 record

PredictImmune technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PredictImmune partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

PredictImmune competitors and assessment

Company assessment

Direct peers

  • Prometheus Laboratories: Prometheus (a Nestlé Health Science company) develops and markets IBD diagnostic and prognostic testing (e.g., IBD Serology 7, PROMETHEUS® Crohn's Prognostic) — directly comparable to PredictImmune as both serve gastroenterologists with biomarker-based prognosis to inform treatment decisions in Crohn's disease and ulcerative colitis.
  • Exagen Inc. Exagen markets proprietary blood-based diagnostic and prognostic tests for autoimmune diseases (e.g., AVISE CTD, AVISE Lupus Prognostic) and sells its assays through a CLIA lab to rheumatologists — directly analogous to PredictImmune's physician-facing prognostic-testing model in immune-mediated disease.

Broad incumbents

  • Myriad Genetics: Myriad is an established molecular diagnostics company offering prognostic and predictive tests (e.g., Vectra DA for RA disease activity, risk-assessment panels) that target specialists managing autoimmune/immune-mediated disease — comparable as a broad incumbent providing physician-facing prognostic biomarker testing.
  • Eurofins Scientific: Eurofins operates a global specialty diagnostics and clinical-testing platform, including autoimmune and IBD biomarker services to clinicians; relevant as a broad incumbent that could partner with, acquire, or compete against PredictImmune's prognostic testing platform.

Emerging players

  • Adaptive Biotechnologies: Adaptive applies immune-receptor sequencing and immune-profiling to characterize immune-mediated disease states and predict clinical outcomes, analogous to PredictImmune's biomarker-based prognosis in immune-mediated conditions — a partial-overlap emerging player with an adjacent technology platform.
  • CareDx: CareDx is a specialty diagnostics company whose AlloSure/AlloMap franchise monetizes prognostic biomarker testing paid for by transplant centers and payers — relevant as a comparable commercial model where a single-disease prognostic biomarker test is sold into a specialist physician channel.
  • Vedanta Biosciences: Vedanta develops microbiome-based therapies for immune-mediated disease (including IBD) and operates in the same clinical/scientific Cambridge-cluster ecosystem; comparable as an immune-mediated-disease platform company pursuing biomarker-driven patient stratification in overlapping indications.
  • Progentec Diagnostics: Progentec develops biomarker-driven diagnostics for autoimmune diseases (e.g., lupus, RA) intended to predict flares and disease progression — a direct functional competitor in the physician-facing prognostic-test niche that PredictImmune targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

PredictImmune social profiles

Digital presence

PredictImmune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PredictImmune leadership team

Management profile

Number of profiles

Profiles6 records

PredictImmune funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PredictImmune M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PredictImmune

What does PredictImmune do?

PredictImmune develops and provides tools to physicians for use in the treatment of patients with immune-mediated disease, focused on predicting long-term clinical prognosis. The company applies proprietary biomarker science and predictive analytics to translate complex immunological data into clinically actionable long-term outcome forecasts that support personalized treatment planning.

When was PredictImmune founded?

PredictImmune was founded in 2017. It employs 11 to 50 people.

Where is PredictImmune based?

PredictImmune is headquartered in Cambridge, United Kingdom, in the Europe region.

Who are PredictImmune's main competitors?

Direct peers on record are Prometheus Laboratories and Exagen Inc.. Broad incumbents are Myriad Genetics and Eurofins Scientific. Emerging players are Adaptive Biotechnologies, CareDx, Vedanta Biosciences and Progentec Diagnostics.

Does PredictImmune have an API?

No public API is recorded for PredictImmune.

What industry is PredictImmune in?

PredictImmune's product category is Clinical Prognostics Software. Its primary akta.pro industry code is HLAAAMAE, Predictive Biomarkers for Therapy Selection (response/non-response stratification), with a secondary code of HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudPredictImmune secures £10m fundingPredictImmune, a Cambridge-based healthtech firm, secured a £10m funding package from new investors BGF and Cambridge Innovation Capital. The funds will support global commercial expansion and its product pipeline for immune-mediated diseases like Crohn's and ulcerative colitis.London Business NewsPredictImmune secures £10m funding - London Business NewsPredictImmune, a developer of prognostic tools for immune-mediated diseases, secured a £10m funding package led by BGF and CIC. The funds will support global commercial expansion and its product pipeline, following earlier investments. The company aims to accelerate international commercialisation and develop new tools.FinSMEsPredictImmune Closes £10M Series B FundingPredictImmune, a Cambridge-based developer of prognostic tools for immune-mediated diseases, raised £10M in Series B funding from Parkwalk, Cambridge Enterprise, BGF, and Cambridge Innovation Capital. The company will use the funds to expand commercial operations across Europe, the USA, and other regions, and to develop new products for autoimmune conditions like lupus.FinSMEsPredictImmune Secures £4.3M from Wellcome TrustPredictImmune, a UK-based developer of prognostic tools for immune-mediated diseases, received £4.3m from the Wellcome Trust. The funding will support a multi-centre clinical trial of its biomarker test for Crohn's disease, led by Andrew Sandham. The company previously raised £4.7m in Series A equity funding in May 2017.